Ocular implant with therapeutic agents and methods thereof
Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
1. A method of treating an ocular disorder, comprising:
introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber, wherein the implant comprises a proximal seat, an intermediate shank adapted to extend through ocular tissue, and a pin having one or more barbs, wherein the pin forms a distal portion of the implant;
implanting the implant into eye tissue adjacent the anterior chamber such that the seat of the implant resides in the anterior chamber following implantation and the pin having one or more barbs penetrates at least partially through a back wall of Schlemm's canal;
eluting a therapeutic agent from the implant into the eye; and
controlling release of the therapeutic agent from the implant.
2. The method of claim 1 , wherein controlling release comprises controlling release of the therapeutic agent at a chosen rate.
3. The method of claim 2 , wherein the chosen rate is episodic or periodic.
4. The method of claim 1 , wherein controlling release comprises controlling release of the therapeutic agent for a selected duration.
5. The method of claim 4 , wherein the selected duration is episodic or periodic.
6. The method of claim 1 , wherein controlling release comprises controlling release of the therapeutic agent at a chosen rate and for a selected duration.
7. The method of claim 6 , wherein the chosen rate and/or the selected duration are episodic or periodic.
8. The method of claim 1 , wherein eluting a therapeutic agent from the implant comprises eluting the therapeutic agent into the anterior chamber.
9. The method of claim 1 , wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.
10. The method of claim 1 , wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.
11. The method of claim 1 , wherein the therapeutic agent is contained within the implant.
12. The method of claim 1 , wherein the therapeutic agent is coated on the implant.
13. The method of claim 1 , wherein introducing an implant into an anterior chamber of an eye involves forming an incision proximate a limbus of the eye.
14. The method of claim 13 , wherein the incision is self-sealing.
15. An ocular implant comprising:
a proximal seat, sized and shaped to reside in an anterior chamber of an eye;
a pin having one or more barbs, wherein the pin forms a distal portion of the implant and the one or more barbs are adapted to anchor the implant in;
a shank disposed between the seat and pin and adapted to extend through ocular tissue, and
a therapeutic agent.